Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov 1;7(11):1716-1718.
doi: 10.1001/jamaoncol.2021.4390.

Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

Noa Eliakim-Raz  1   2   3 , Amir Massarweh  4 , Amos Stemmer  5 , Salomon M Stemmer  3   4
Affiliations
Comment

Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

Noa Eliakim-Raz et al. JAMA Oncol. .

Abstract

This cohort study examines the durability of immune response from BNT162b2 vaccination for severe acute respiratory syndrome coronavirus 2 in patients with cancer vs healthy controls.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr S.M. Stemmer received research grants (to the institution) from CAN-FITE, AstraZeneca, Bioline RX, BMS, Halozyme, Clovis Oncology, CTG Pharma, Exelixis, Geicam, Incyte, Lilly, Moderna, Teva Pharmaceuticals, and Roche, and owns stocks and options in CTG Pharma, DocBoxMD, Tyrnovo, VYPE, Cytora, and CAN-FITE. The remaining authors declare no conflicts of interest.

Figures

Figure.
Figure.. Immunoglobulin G (IgG) Values of Study
A, IgG values by group. B, Scatter plot of IgG values vs days postvaccination for patients with cancer. C, Scatter plot of IgG values vs days postvaccination for controls. In panels B and C, the shaded areas indicate 95% CIs and the black dots represent individual participants.
See this image and copyright information in PMC

Comment on

References

    1. Massarweh A, Eliakim-Raz N, Stemmer A, et al. . Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. Published online May 28, 2021. doi:10.1001/jamaoncol.2021.2155 - DOI - PMC - PubMed
    1. Foundation R. The R Project for Statistical Computing. Accessed June 27, 2021. http://www.r-project.org/
    1. Widge AT, Rouphael NG, Jackson LA, et al. ; mRNA-1273 Study Group . Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384(1):80-82. doi:10.1056/NEJMc2032195 - DOI - PMC - PubMed
    1. Doria-Rose N, Suthar MS, Makowski M, et al. ; mRNA-1273 Study Group . Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med. 2021;384(23):2259-2261. doi:10.1056/NEJMc2103916 - DOI - PMC - PubMed
    1. Harvey RA, Rassen JA, Kabelac CA, et al. . Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Intern Med. 2021;181(5):672-679. doi:10.1001/jamainternmed.2021.0366 - DOI - PMC - PubMed